GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 233 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is 1.21 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $12,449,838,000 | +2765.8% | 182,817 | +1244.5% | 0.02% | +1900.0% |
| Q2 2022 | $434,424,000 | +146.0% | 13,597 | +166.8% | 0.00% | – |
| Q1 2022 | $176,560,000 | -53.5% | 5,097 | -60.7% | 0.00% | -100.0% |
| Q4 2021 | $379,603,000 | +39.0% | 12,969 | +21.0% | 0.00% | – |
| Q3 2021 | $273,120,000 | +50.0% | 10,719 | +106.1% | 0.00% | – |
| Q2 2021 | $182,104,000 | +87.0% | 5,200 | +117.6% | 0.00% | – |
| Q1 2021 | $97,392,000 | -48.4% | 2,390 | -45.2% | 0.00% | – |
| Q4 2020 | $188,832,000 | +44.9% | 4,360 | +84.5% | 0.00% | – |
| Q3 2020 | $130,296,000 | -87.9% | 2,363 | -86.1% | 0.00% | -100.0% |
| Q2 2020 | $1,072,516,000 | -71.1% | 16,989 | -76.6% | 0.00% | -75.0% |
| Q1 2020 | $3,708,674,000 | +364.0% | 72,591 | +621.9% | 0.01% | +700.0% |
| Q4 2019 | $799,351,000 | -42.1% | 10,056 | -64.6% | 0.00% | -50.0% |
| Q3 2019 | $1,379,666,000 | +32.2% | 28,435 | +43.3% | 0.00% | 0.0% |
| Q2 2019 | $1,043,637,000 | +57.5% | 19,841 | +58.4% | 0.00% | +100.0% |
| Q1 2019 | $662,789,000 | +33.7% | 12,522 | +3.7% | 0.00% | 0.0% |
| Q4 2018 | $495,679,000 | -76.6% | 12,075 | -78.4% | 0.00% | -66.7% |
| Q3 2018 | $2,119,488,000 | -27.4% | 55,776 | -13.7% | 0.00% | -40.0% |
| Q2 2018 | $2,919,875,000 | -56.8% | 64,599 | -53.8% | 0.01% | -61.5% |
| Q1 2018 | $6,759,633,000 | +2131.5% | 139,951 | +1718.0% | 0.01% | +1200.0% |
| Q4 2017 | $302,916,000 | +124.5% | 7,698 | +77.2% | 0.00% | – |
| Q3 2017 | $134,912,000 | +8.5% | 4,345 | -4.4% | 0.00% | – |
| Q2 2017 | $124,360,000 | +490.0% | 4,547 | +694.9% | 0.00% | – |
| Q1 2017 | $21,078,000 | +13.0% | 572 | -55.7% | 0.00% | – |
| Q4 2016 | $18,655,000 | -43.4% | 1,291 | -9.7% | 0.00% | – |
| Q3 2016 | $32,938,000 | +257.7% | 1,429 | +157.5% | 0.00% | – |
| Q2 2016 | $9,207,000 | +409.2% | 555 | +386.8% | 0.00% | – |
| Q1 2016 | $1,808,000 | -95.6% | 114 | -91.1% | 0.00% | – |
| Q4 2015 | $41,448,000 | -23.3% | 1,282 | +0.1% | 0.00% | – |
| Q3 2015 | $54,007,000 | – | 1,281 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alerce Investment Management, L.P. | 356,270 | $24,262,000 | 23.36% |
| Twin Securities, Inc. | 376,669 | $25,651,000 | 11.94% |
| Paradigm Biocapital Advisors LP | 1,175,879 | $80,077,000 | 10.68% |
| Chicago Capital Management, LLC | 246,246 | $16,769,000 | 9.12% |
| HARVEST MANAGEMENT LLC | 141,500 | $9,636,000 | 7.78% |
| Fernwood Investment Management, LLC | 174,724 | $11,899,000 | 5.02% |
| ArchPoint Investors | 168,725 | $11,490,000 | 4.69% |
| HAVENS ADVISORS LLC | 46,000 | $3,133,000 | 4.69% |
| Perceptive Advisors | 2,322,247 | $158,145,000 | 4.59% |
| Crabel Capital Management, LLC | 112,680 | $7,674,000 | 4.48% |